Exploiting antibody biology for the treatment of cancer

Vidhi Devendra Khanna, Jayanth Panyam, Thomas S. Griffith

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Over the last decade, antibodies have become an important component in the arsenal of cancer therapeutics. High-specificity, low off-target effects, desirable pharmacokinetics and high success rate are a few of the many attributes that make antibodies amenable for development as drugs. To design antibodies for successful clinical applications, however, it is critical to have an understanding of their structure, functions, mechanisms of action and pharmacokinetic/pharmacodynamic properties. This review highlights some of these key aspects, as well as certain limitations encountered, with monoclonal antibody therapy. Further, we discuss rational combination therapies for clinical applications, some of which could help overcome the limitations.

Original languageEnglish (US)
Pages (from-to)255-267
Number of pages13
Issue number4
StatePublished - Mar 2020

Bibliographical note

Publisher Copyright:
© 2020 Future Medicine Ltd.


  • cancer
  • combinations
  • mechanisms
  • monoclonal antibodies
  • structure

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Exploiting antibody biology for the treatment of cancer'. Together they form a unique fingerprint.

Cite this